ABSTRACT: In asthma, human airway epithelial cells (HAECs) regulate the intensity of mucosal inflammation, in part, by releasing the pro-inflammatory cytokine interleukin (IL)-1b. However, the IL-1b inhibitors, IL-1 receptor antagonist (IL-1RA) and soluble IL-1 receptor type II (sIL-1RII), regulate IL-1b bioactivity. In order to better understand the control of IL-1b activity in the airway mucosa, the role(s) of tumour necrosis factor (TNF)-a, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in the release of IL-1b and its inhibitors by cultured HAECs were examined.
Human airway epithelial cells (HAECs) release a variety of cytokines and chemokines which regulate the intensity of mucosal inflammation [1, 2] . For example, the proinflammatory cytokine, interleukin (IL)-1b, which is produced by HAECs, is thought to play an important role in the pathogenesis of asthma [2] [3] [4] [5] [6] [7] [8] [9] . IL-1b levels are increased in bronchoalveolar lavage fluid in asthma and these levels correlate with the severity of airway dysfunction [3, 4] . Furthermore, IL-1b immunoreactivity is increased in tracheobronchial epithelial cells in asthmatic compared to normal subjects [5] .
The mechanism(s) by which IL-1b produced by HAECs alters airway structure and function in asthma are relatively well understood. For example, IL-1b-induced release of cytokines (e.g. regulated on activation, normal T-cell expressed and secreted, granulocyte-macrophage colony-stimulating factor, eotaxin, monocyte chemotactic peptide-4, IL-5, etc.) from HAECs augments eosinophil chemotaxis, survival and activation [9] [10] [11] . In eosinophils, IL-1b induces release of IL-9, the T-cell and mast cell growth factor, which induces airway eosinophilia, airway hyperreactivity and goblet cell metaplasia. Moreover, IL-1b stimulates release of fibroblast growth factors (e.g. platelet-derived growth factor) by HAECs, which enhance fibroblast proliferation and collagen synthesis, thereby contributing to airway remodelling [9, 12] . Finally, IL-1b impairs cyclic adenosine monophosphate (cAMP) production in HAECs in response to b 2 -adrenergic agonists, thereby impairing mucociliary clearance [13] .
In contrast to the considerable knowledge regarding the biological effects of IL-1b produced by HAECs, the regulation of IL-1b release and bioactivity is poorly understood. Work in other tissues/cell types indicates that IL-1b bioactivity is closely regulated by a complex system of response modifiers, including a receptor antagonist (IL-1 receptor antagonist (IL-1RA)), which binds to but does not activate the receptor, a membrane-bound decoy receptor (the type II receptor), and soluble forms of the two IL receptors (sIL-1RI and sIL-1RII) [8, 9] .
Studies in nonrespiratory cells (e.g. blood monocytes and peritoneal macrophages) suggest that IL-1b activity in the airway may be affected by several factors relevant to asthma and chronic obstructive pulmonary disease (COPD). In monocytes and macrophages, extracellular release of members of the IL-1b cytokine family is controlled by the proinflammatory cytokine, tumour necrosis factor (TNF)-a, and cyclic nucleotides (e.g. cAMP) [14, 15] . In asthma and COPD, TNF-a levels in the airway are increased and correlate with the severity of airway obstruction [16, 17] . In both diseases, b 2 -adrenergic agonist bronchodilators and theophylline increase intracellular cAMP levels. Finally, increases in airway nitric oxide levels in asthma may increase cyclic guanosine monophosphate (cGMP) levels by activating guanylyl cyclase. Accordingly, it was hypothesised that release of IL-1b and its family of inhibitors by HAECs is regulated by TNF-a and changes in intracellular cAMP and cGMP levels. This hypothesis was tested in cultured HAECs by examining the effects of TNF-a, cAMP and cGMP on the release of IL-1b, IL-1RA and sIL-1RII into the cell culture medium.
Materials and methods

Cell culture and stimulation
Experiments were performed using the HAEC line 16-HBE. Cells were cultured in Dulbecco modified Eagle medium (Biosource, Rockville, MD, USA) supplemented with 10% foetal bovine serum (Sigma, St Louis, MO, USA), penicillin (100 U?mL -1 ) and streptomycin (100 mg?mL -1 ) in 100-mmdiameter tissue culture dishes in an atmosphere of 5% carbon dioxide/95% air at 37uC until confluent. Dishes were precoated with type VI human placental collagen (Sigma). In three experiments, primary cultures of normal human primary epithelial cells (NHBEs; Cambrex Bioscience, Walkersville, MD, USA) were studied. NHBEs were grown in collagencoated, six-well plates in bronchial epithelial cell basal medium (Cambrex Bioscience) enriched with 52 mg?mL ) for 2-30 h. The maximum concentrations of all three cytokines occurred at 24 h. Thereafter, cells were treated for 24 h with TNF-a (2-200 ng?mL -1 ), dibutyryl cAMP (0.01-1 mM), or 8-bromo-cGMP (0.01-1 mM). In separate experiments, the interactive effects of TNF-a and the cyclic nucleotides were determined. In these experiments, cells were treated with TNF-a (20 ng?mL -1 ) alone or in combination with either dibutyryl cAMP (1 mM) or 8-bromo-cGMP (1 mM). Finally, the role of protein kinase A (PKA) and protein kinase G (PKG) pathways in mediating the effects of dibutyryl cAMP and 8-bromo-cGMP were examined using the PKA and PKG inhibitors, KT 5720 and KT 5823 (Calbiochem, La Jolla, CA, USA; 0.1-10 mM), respectively. Inhibitors were added 1 h before TNF-a alone or in combination.
After treatment, the cell-conditioned medium was collected and concentrated 20-fold by centrifugation in Centricon Plus-20 filters (Millipore, Billerica, MA, USA) for 30-90 min at 2,8006g at 4uC. Samples were stored at -20uC prior to assay. After the medium was collected, cells were detached using 0.05% trypsin and 0.53 mM ethylenediamine tetra-acetic acid (EDTA) in Hank9s balanced salt solution and viability assessed by trypan blue (0.4%) exclusion. In all experiments, epithelial cell viability was w90%.
Cytokine assays
IL-1b, IL-1RA and sIL-1RII levels in the epithelial cellconditioned medium were measured by solid-phase sandwich enzyme-linked immunosorbent assay in 96-well microtitre plates.
IL-1b concentration was measured using two different mouse antihuman monoclonal antibodies (immunoglobulin (Ig) G1) directed against IL-1b (Biosource International, Camarillo, CA, USA). A separate biotin-conjugated mouse monoclonal antibody (IgG1 k chain) (0.2 mg?mL
; Biosource International) was used for detection. The antigen/antibody conjugate was detected colorimetrically by the addition of horseradish peroxidase (HRP)-conjugated streptavidin followed by tetramethylbenzidine (TMB) as substrate. Colour intensity at 450 nm was measured using a microplate reader (Bio-Rad model 550; Bio-Rad, Hercules, CA, USA). Samples were assayed in triplicate. Concentrations in sample media were calculated by interpolation from a standard curve using recombinant human IL-1b as the standard. The threshold of detection in the IL-1b assay was v0.19 pg?mL -1 . IL-1RA concentration was measured using a single mouse antihuman monoclonal antibody (IgG1) directed against IL-1RA and the same biotin/streptavidin detection system as described above for IL-1b. The antibody used to measure IL-1RA recognised all three isoforms of IL-1RA. The threshold of detection in the IL-1RA assay was y4 pg?mL -1 . sIL-1RII concentration in epithelial cell-conditioned medium was measured using a mouse antihuman monoclonal antibody directed against sIL-1RII (R&D Systems, Minneapolis, MN, USA). sIL-1RII rather than sIL-1RI was measured since the type II receptor predominates over the type I receptor in epithelial cells [18, 19] , and sIL-1RII exhibits greater affinity for IL-1b than does sIL-RI [20] . A separate HRP-conjugated rabbit polyclonal antibody directed against human sIL-1RII was used for detection of the antigen/ antibody complex (R&D Systems) and the reaction monitored as described for the IL-1b assay. The threshold of detection in the sIL-1RII assay was v10 pg?mL -1 .
Statistical analysis
Comparison of mean values in control and experimental groups was performed by paired t-test. In order to normalise for differences in cell responses to the various stimuli, data were also expressed as a percentage of the control value (vehicle-treated cells). TNF-a, dibutyryl cAMP, 8-bromocGMP, and PKA and PKG inhibitor dose/response effects on cytokine concentration were assessed by one-way repeated measures analysis of variance (ANOVA). Significance of differences in group mean values was taken at the pv0.05 level.
Results
Cultured 16-HBE cells and primary cultures of HAECs constitutively released IL-1b, IL-1RA and sIL-1RII into the medium (table 1) . However, the IL-1b level, expressed in terms of molarity, was y100-fold lower than that of IL-1RA and y550-fold lower than that of sIL-1RII. ) caused an increase in IL-1b, IL-1RA and sIL-1RII levels over 24 h (all pv0.001 (ANOVA)) ( fig. 1) . However, the nature and magnitude of the response of the three IL-1b cytokine family members to TNF-a differed. For example, increases in IL-1b were progressive over the entire range of TNF-a concentrations, whereas increases in IL-1RA and sIL-1RII reached a plateau at 20 ng?mL -1 TNF-a. In addition, increases in IL-1b level were proportionately greater (i.e. y8-fold) than those in IL-1RA and sIL-1RII (y1.4-2-fold).
Effects of cAMP and cGMP
Dibutyryl cAMP (1 mM) treatment increased IL-1b release both alone and in the presence of TNF-a ( fig. 2a) . Conversely, dibutyryl cAMP had no effect on IL-1RA release but reduced both constitutive and TNF-a-induced sIL-1RII release ( figs. 3a and 4a) .
In contrast to the effects of dibutyryl cAMP, 8-bromocGMP (1 mM) significantly reduced IL-1RA and sIL-1RII release in both the absence and presence of TNF-a (figs. 3b and 4b), but had no effect on IL-1b (fig. 2b) .
The effects of dibutyryl cAMP and 8-bromo-cGMP varied with dose, and were greatest at a concentration of 1 mM (table 2) .
Effect of PKA and G inhibitors on responses to dibutyryl cAMP and 8-bromo-cGMP
The PKA inhibitor, KT 5720, abolished the dibutyryl cAMP (1 mM)-induced increase in IL-1b release (pv0.01) but had no effect on inhibition of sIL-1RII release (table 3) . The PKG inhibitor, KT 5823, reversed the 8-bromocGMP-induced inhibition of IL-1RA release (pv0.01) but had no effect on inhibition of sIL-1RII release (table 4) .
IL-1b cytokine release by primary cultures of NHBE cells: response to TNF-a and cAMP
NHBEs produced IL-1b, IL-RA and sIL-1RII constitutively (three experiments). It is of interest that IL-1b and IL-RA concentrations (48 ¡ 15 and 527 ¡ 76 pg?mL -1 , respectively) exceeded those in 16-HBE cells. In contrast, sIL-1RII concentrations (31 ¡ 3 pg?mL -1 ) were lower than those produced by 16-HBE cells.
TNF-a stimulation induced responses by NHBEs which resembled those of 16-HBE cells (three experiments) (fig. 5).
Finally, dibutyryl cAMP (1 mM for 24 h), given to cells stimulated with 20 ng?mL -1 TNF-a, produced similar effects on IL-1b and sIL-1RII release (three experiments) to those that were observed in 16-HBE cells (data not shown). 
Discussion
The biological effects of IL-1b in the respiratory tract depend on the concentration of IL-1b relative to those of its several inhibitors [9] . Three forms of IL-1b inhibitor have been described: 1) IL-1RA, which competitively binds the functionally active type I receptor but does not induce a signal; 2) the type II receptor, which has a truncated intracytoplasmic domain that renders it functionally inactive; and 3) soluble forms of the two types of IL-1 receptor (sIL-1RI and sIL-1RII), which are shed by activated cells and which reversibly bind IL-1b.
Adding to this complexity, three isoforms of IL-1RA have been described (i.e. secretory IL-1RA and two isotypes of intracellular IL-1RA (types I and II)) [9] . Secretory IL-1RA is largely expressed in inflammatory cells such as monocytes and neutrophils [21] . In contrast, both isotypes of intracellular IL-1RA are expressed by keratinocytes and epithelial cells of the tracheobronchial tree, nose, cornea and gastrointestinal tract [21, 22] . Indeed, in HAECs, intracellular IL-1RA is secreted as well as retained intracellularly [22] . It is of note that the antibody used in the present study detected all three isoforms of IL-1RA.
On cell activation, both IL-1 receptor types are cleaved from the cell surface to generate soluble forms which reversibly bind and inactivate IL-1b [18] . It is of interest that, in epithelial cells, the decoy type II receptors outnumber type I receptors [18, 19] . Moreover, sIL-1RII has greater affinity for IL-1b than for IL-1RA and inhibits IL-1b more potently than does sIL-1RI [20] . As a result, in the airway epithelium, sIL-1RII is probably the functionally more important of the two soluble receptors.
To the present authors9 knowledge, the present experiments are the first to simultaneously examine release of IL-1b and its major inhibitors by HAECs. Moreover, for the first time, the release by HAECs of sIL-1RII, an important inhibitor of IL-1b, is described. The results of the present study indicate that HAECs constitutively release IL-1b, IL-1RA and sIL-1RII. However, the concentrations of IL-1RA and sIL-1RII produced constitutively are far greater than that of IL-1b in both 16-HBE cells and NHBEs.
HAECs make an important contribution to the pathogenesis of mucosal inflammation, in part by producing IL-1b. The results of the present study suggest that, under basal conditions, the greater concentrations of IL-1RA and sIL-1RII relative to IL-1b present in the extracellular space of airway epithelial cells should have the effect of inactivating IL-1b. Supporting this concept is the observation by COULTER et al. [23] that a 10-100-fold molar excess of IL-1RA or a 100-1,000-fold molar excess of sIL-1RII relative to IL-1b completely inhibits IL-1b activity (as assessed from IL-1b-induced IL-8 release). In consequence, the present data Data are presented as mean¡SEM percentage of controls. Cells were treated with 20 ng?mL -1 tumour necrosis factor-a alone or in combination with 1 mM dibutyryl cyclic adenosine monophosphate in the presence of the concentration of KT 5720 indicated. suggest that, under "normal" conditions, HAECs exert an "anti-inflammatory" bias in the mucosa, at least as regards the IL-1b family.
TNF-a increased the release of all three cytokines (IL-1b, IL-1RA and sIL-1RII). Interestingly, however, the TNF-a responses of the three cytokines differed. In the case of IL-1b, the increases were progressive over the entire range of TNF-a concentrations. In contrast, increases in IL-1RA and sIL-1RII were maximal at 20 ng?mL -1 TNF-a. Furthermore, TNF-a-induced increases in IL-1b release were proportionately greater than those in IL-1RA and sIL-1RII. It is of note in this regard that TNF-a concentrations in bronchoalveolar lavage fluid correlate with the severity of airway obstruction in subjects with asthma [1] . Accordingly, these data suggest that, under the conditions which exist in asthma, HAECs may promote inflammation in response to TNF-a by releasing disproportionately greater amounts of IL-1b than of IL-1RA and sIL-1RII. Furthermore, agents which increase cAMP production (e.g. b 2 -adrenergic bronchodilators and prostaglandin E 2 (PGE 2 )), which would stimulate IL-1b release while inhibiting IL-1RA and sIL-1RII release, would add to this effect. It is of interest in this regard that IL-1b induces expression of phospholipase A 2 and PGE 2 production in HAECs [24] . PGE 2 , in turn, strongly stimulates cAMP production in HAECs, suggesting that an autocrine selfamplifying loop exists [25] . This amplification loop may contribute to the exponential increase in IL-1b release observed with increasing TNF-a concentration [25] . Finally, nitric oxide-induced increases in intracellular cGMP would tend to reduce IL-1RA and sIL-1RII levels relative to IL-1b.
Increases in cAMP concentration augmented constitutive and TNF-a-induced IL-1b release but inhibited IL-1RA and sIL-1RII release. PKA-dependent pathways were entirely responsible for the IL-1b response to dibutyryl cAMP, as evidenced by the fact that the specific PKA inhibitor, KT 5720, completely reversed this effect. However, KT 5720 did not reverse the dibutyryl cAMP effects on IL-1RA and sIL-1RII, suggesting that PKA-independent pathways control the release of these cytokines.
In contrast to the response to dibutyryl cAMP, 8-bromocGMP had no effect on IL-1b release, but inhibited constitutive and TNF-a-induced release of IL-1RA and sIL-1RII. KT 5823 inhibited the effects of 8-bromo-cGMP on IL-1RA, suggesting that PKG-dependent pathways control release of IL-1RA and sIL-1RII. Conversely, effects of 8-bromo-cGMP on sIL-1RII release were not altered by KT 5823, indicating that PKG-independent pathways control the release of sIL-1RII.
Comparison with previous studies
Prior studies have demonstrated release of IL-1b by HAECs in response to nitrogen dioxide and diisocyanate [26, 27] , and release of IL-1RA in response to IL-4, IL-13 and interferon-c [22, 28] . COULTER et al. [23] demonstrated that HAECs and human alveolar epithelial (A549) cells both produce IL-1RA. It is of interest that IL-1RA release by HAECs was y60-fold higher than that from alveolar epithelial cells.
In contrast to the present results, however, COULTER et al. [23] failed to detect sIL-IRII or the corresponding messenger ribonucleic acid in HAECs or A549 cells. The differing results obtained in the present study and that of COULTER et al. [23] are difficult to explain. However, differences in cell culture conditions may have contributed to the differing results obtained. For example, COULTER et al. [23] appear to have grown human epithelial cells on tissue culture plastic. The present cells were grown on a collagen matrix which stimulates the production and release of IL-1b and IL-1RA by cultured human blood mononuclear cells [29] . Growing cells on a collagen substrate could conceivably also have stimulated sIL-1RII expression in HAECs in the present study.
The present data on the effects of TNF-a and cAMP on IL-1b cytokine family member release by HAECs are compatible with data obtained in other cell systems. For example, in lipopolysaccharide-stimulated human promyelocytes, increases in intracellular cAMP levels enhance transcription and release of IL-1b [30] . Similar results have been obtained in rat hypothalamic microglia [31] . It is of interest that the effects of cAMP on IL-1b release are cell type-dependent, however. For example, increases in cAMP or stimulation with b-adrenergic agonists inhibit IL-1b production in human blood monocytes, mouse peritoneal macrophages and hypothalamic astrocytes [14, 15, 31] .
Conclusion
In summary, the results of the present study demonstrate that release of interleukin-1b, interleukin-1 receptor antagonist and soluble interleukin-1 receptor type II by human airway epithelial cells is: 1) constitutively biased towards greater release of inhibitors relative to interleukin-1b; 2) enhanced by tumour necrosis factor-a; and 3) differentially affected by tumour necrosis factor-a, cyclic adenosine monophosphate and cyclic guanosine monophosphate such that the ratio of inhibitors to interleukin-1b is reduced.
